Exchange: NYSE·Updated 05:23 AM EDT
RCUS logo

RCUS Arcus Biosciences Inc

$22.77
$0.65
(2.94%)
Pre-Market
Prev Close $22.12
EarningsOct 27
Mkt Cap$2.82B
Vol7.00

About RCUS

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
76

Extremely Bullish Sentiment

How do you feel about RCUS?

stcks
$RCUS updated with JPMorgan initiates Arcus Biosciences stock at Overweight, $41 target added!
1
EndGD
$RCUS why does TD Cowen see a +50-100% upside or 60% downside on next week data? Trying to understand what makes this readout so binary
1
Theobviouschoice
$RCUS next week is one to watch🚀🚀🚀. This week is stealing shares form the weak hands. 😀 Good Luck - you will need it!
1
stcks
$RCUS catalyst next 180 days casdatifan (ccRCC) lead - Oct 20, 8:30 AM ET investor event — ARC-20 data across 1L / 2L / late-line (highest near-term) - PEAK-1 Ph3 enroll complete + PEAK-20 start targeted YE 2026 - Combo collabs rolling (BMS/BioNTech, Summit/ivonescimab mid-2027 data, AVEO tivozanib Q4 start) - Queliclustat PRISM-1 (PDAC): 1H 2027
1
stcks
$RCUS Other than Wall Street playing the game again. The only news or catalyst was the recent announcement of an October 20th investor event with fresh Casadifan kidney-cancer data across multiple lines. No reasons to believe it will be negative, just the opposite.
1

Advertisement|Remove ads.